Mitomycin
- PDF / 130,639 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 65 Downloads / 148 Views
1
S
Haemolytic uraemic syndrome treated with eculizumab: case report A woman developed haemolytic uraemic syndrome following treatment with mitomycin for metastatic breast cancer [patient age not stated]; she was treated with eculizumab. The woman developed haemolytic uraemic syndrome while receiving mitomycin for relapsing metastatic breast cancer [route, dosage and duration of treatment to reaction onset not stated]. Mitomycin was withdrawn, and daily plasma exchanges were initiated; however, haematological parameters failed to improve, and dialysis was initiated. Accordingly, eculizumab 900mg was infused 30 days following haemolytic uraemic syndrome diagnosis. The woman’s haematological parameters quickly improved; within 7 days, normalisation of lactate dehydrogenase and platelet count values were noted. Eculizumab was infused seven more times and after 3 months partial recovery of renal function was noted. At follow-up, over 18 months, stable renal function without relapse of haemolytic uraemic syndrome was noted. Author comment: "Several drugs, including mitomycin-C and interferon-β, may also trigger HUS [haemolytic uraemic syndrome]". Faguer S, et al. Eculizumab and drug-induced haemolytic-uraemic syndrome. Clinical Kidney Journal 6: 484-485, No. 5, Oct 2013. Available from: URL: http:// 803095328 dx.doi.org/10.1093/ckj/sft078 - France
0114-9954/13/1477-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
Reactions 9 Nov 2013 No. 1477
Data Loading...
